A Phase 3 interventional study of CD5789 (trifarotene) 50μg/g cream and Placebo cream in Acne Vulgaris, sponsored by Galderma R&D. Completed at 124 sites in 5 countries. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2019-11-12.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing trifarotene in Acne Vulgaris — none open to participants now, 1 under way, 1 of them phase 3. trifarotene · Acne Vulgaris.
Among the 12 studies testing trifarotene in Acne Vulgaris, this one is the 2nd largest by enrollment, is one of 3 that started in 2015, is one of 6 in phase 3, and was the 4th registered.
791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.
Browse Acne Vulgaris studies →None of the 12 studies testing trifarotene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →
trifarotene: first FDA approval 2019 (AKLIEF). What it is approved for, and how studies give it, is on its page →
Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 9 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2015.
This study's enrollment of 1,208 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 507 across the 12 interventional studies. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 3 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
49 studies in Acne Vulgaris by Galderma Group AG: none open now, 1 under way, 1 of them phase 3. Of 48 finished, 39 (81%) have results posted.
Among the 49 studies in Acne Vulgaris by Galderma Group AG, this one is the 4th largest by enrollment of the 46 interventional ones that give a count, is one of 5 that started in 2015, is one of 20 in phase 3, and was the 38th registered.
Galderma Group AG’s Acne Vulgaris studies by the year they started, since 2004.
1 of the studies testing trifarotene in Acne Vulgaris that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186413Phase 3Galderma R&DA Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing trifarotene in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 49 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Assessment of the efficacy and safety of CD5789 (trifarotene) 50μg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
Clinical Trial for each subject is approximately 14 weeks and are randomized to one of the two treatments for 12 weeks. Subjects must be 9 years of age and older with acne vulgaris.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD5789 (trifarotene) 50μg/g Cream
Drug: CD5789 (trifarotene) 50μg/g cream
Placebo cream
Drug: Placebo cream
Drug page: Trifarotene
CD5789 (trifarotene) 50µg/g cream applied once daily for 12 weeks.
Placebo cream applied once daily for 12 weeks
Investigator Global Assessment (IGA) Success Rate at Week 12
Number of subjects who achieved an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12.
Time frame: From Baseline to Week 12
| Milestone | CD5789 (Trifarotene) 50μg/g Cream | Placebo Cream |
|---|---|---|
| Started | 612 | 596 |
| Completed | 540 | 535 |
| Not completed | 72 | 61 |
Number of subjects who achieved an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12.
| Participants | CD5789 (Trifarotene) 50μg/g Cream | Placebo Cream |
|---|---|---|
| Investigator Global Assessment (IGA) Success Rate at Week 12 | 180 | 116 |
Collected over Each participant's adverse events were collected starting at the first visit (screening) until the last visit (Week 12).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CD5789 (Trifarotene) 50μg/g Cream | 0/612 (0%) | 4/612 (0.7%) | 177/612 (28.9%) |
| Placebo Cream | 0/596 (0%) | 2/596 (0.3%) | 74/596 (12.4%) |
| Event | CD5789 (Trifarotene) 50μg/g Cream | Placebo Cream |
|---|---|---|
| Hereditary angioedemaCongenital, familial and genetic disorders | 0/612 | 1/596 |
| Urinary Tract InfectionRenal and urinary disorders | 0/612 | 1/596 |
| Atypical PneumoniaInfections and infestations | 0/612 | 1/596 |
| Facial Bones FractureInjury, poisoning and procedural complications | 1/612 | 0/596 |
| Procedural dizzinessInjury, poisoning and procedural complications | 1/612 | 0/596 |
| Infectious MononucleosisInfections and infestations | 1/612 | 0/596 |
| CellulitisInfections and infestations | 1/612 | 0/596 |
| Event | CD5789 (Trifarotene) 50μg/g Cream | Placebo Cream |
|---|---|---|
| Application Site IrritationGeneral disorders | 66/612 | 4/596 |
| NasopharyngitisInfections and infestations | 24/612 | 27/596 |
| SunburnInjury, poisoning and procedural complications | 27/612 | 5/596 |
| Application Site PruritisGeneral disorders | 24/612 | 8/596 |
| HeadacheNervous system disorders | 6/612 | 12/596 |
| Upper Respiratory Tract InfectionInfections and infestations | 10/612 | 8/596 |
| InfluenzaInfections and infestations | 6/612 | 9/596 |
| Skin IrritationSkin and subcutaneous tissue disorders | 8/612 | 0/596 |
| SinusitisInfections and infestations | 6/612 | 1/596 |
| Age, Categorical(Participants) | CD5789 (Trifarotene) 50μg/g Cream | Placebo Cream | Total |
|---|---|---|---|
| <=18 years | 314 | 278 | 592 |
| Between 18 and 65 years | 298 | 318 | 616 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | CD5789 (Trifarotene) 50μg/g Cream | Placebo Cream | Total |
|---|---|---|---|
| Female | 305 | 324 | 629 |
| Male | 307 | 272 | 579 |
| Ethnicity (NIH/OMB)(Participants) | CD5789 (Trifarotene) 50μg/g Cream | Placebo Cream | Total |
|---|---|---|---|
| Hispanic or Latino | 135 | 148 | 283 |
| Not Hispanic or Latino | 477 | 448 | 925 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | CD5789 (Trifarotene) 50μg/g Cream | Placebo Cream | Total |
|---|---|---|---|
| American Indian or Alaska Native | 11 | 5 | 16 |
| Asian | 23 | 32 | 55 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Black or African American | 47 | 49 | 96 |
| White | 508 | 484 | 992 |
| More than one race | 8 | 10 | 18 |
| Unknown or Not Reported | 14 | 15 | 29 |
| Region of Enrollment(participants) | CD5789 (Trifarotene) 50μg/g Cream | Placebo Cream | Total |
|---|---|---|---|
| Canada | 70 | 69 | 139 |
| Puerto Rico | 27 | 28 | 55 |
| Hungary | 44 | 44 | 88 |
| United States | 407 | 395 | 802 |
| Germany | 64 | 60 | 124 |
| Physician Global Assessment Scale Face(Participants) | CD5789 (Trifarotene) 50μg/g Cream | Placebo Cream | Total |
|---|---|---|---|
| Clear | 0 | 0 | 0 |
| Almost Clear | 0 | 0 | 0 |
| Mild | 0 | 0 | 0 |
| Moderate | 612 | 596 | 1208 |
| Severe | 0 | 0 | 0 |
Showing the first 100 of 124 sites across 5 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2015 to primary completion in Nov 2017, 23 months.
Results were first posted in Aug 2019, 1 year 9 months after primary completion. A results delay was requested in May 2018.
Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 23 months is above that.
Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trifarotene